利可君防治恶性肿瘤放疗所致骨髓抑制的疗效观察

目的：观察利可君片防治恶性肿瘤放疗所致骨髓抑制的疗效。方法：选择我院2010年6月至2012年6月收治的60例接受放疗的恶性肿瘤患者，将其随机分为对照组和观察组，每组各30例，对照组在出现骨髓抑制前对照组不服用任何升血药物，在出现骨髓抑制后给予吉赛欣静脉或皮下注射2～5μg/kg，1次每日；观察组患者放疗前1周开始口服利可君片20mg，3次每日，至放疗结束后2周。比较两组的疗效，骨髓抑制发生时间和发生率，血小板和白细胞水平。结果：两组的疾病控制率和有效率比较无明显差别（P〉0．05）；对照组和观察组骨髓抑制的发生率分别为60．0％和16．7％，观察组显著低于对照组（P〈0．05）；治疗后，观察组血小板和白细胞无明显改变，对照组与治疗前相比明显下降（P〈0．05），且显著低于观察组（P〈0．05）。结论：利可君防治恶性肿瘤放疗所致骨髓抑制的疗效显著，值得临床推广。

Clinical Observation on the efficacy of Leucogen in the Prevention and treatment of Bone Marrow Suppression Induced by Radiotherapy in patients with malignant tumor

Objective： To observe the clinical effect of leucogen in the prevention and treatment of bone marrow suppression induced by radiotherapy in patients with malignant tumor. Methods： 60 cases of malignant tumor treated by radiotherapy from June 2010 to June 2012 in our hospital Were selected and randomly divided into the control group and observation group （30 cases in each group）. The observation group was given 20 mg of leucogen before ＇radiotherapy, three times a day, until the end of radiotherapy. The control group was given 2-5 μg/kg of recombinant human granulocyte colony-stimulating factor unless bone marrow suppression, once a day. The efficacy, incidence rate and occurrence time of bone marrow suppression and, the levels of white blood cells and platelets were compared. Results： There was no significant difference of response rate and disease control rate between the two groups （P〉0.05）. The incidence rate of bone marrow suppression of observation group was 16.7 %, which was significantly lower than that of the control group （60.0 %, P〈0.05）. No significant differences of the levels of white blood cells and platelets was found between before and after treatment in the observation group, but they were significantly decreased in the control group after treatment （P〈0.05）, which was significantly lower than those of the observation group after treatment （P〈0.05）. Conclusion： Leucogen was effective in the prevention and treatment of bone marrow suppression induced by radiotherapy in patients with malignant tumor, it was worthy of being popularized in clinic.